250 mg Progesterone for Adenomyosis
For adenomyosis, 200 mg daily of oral micronized progesterone for 12-14 days per cycle is the recommended dose, not 250 mg. The 250 mg dose is not supported by current evidence or guidelines for this indication.
Recommended Dosing for Adenomyosis
The evidence-based approach for oral micronized progesterone in adenomyosis follows these parameters:
Standard Dosing Protocol
- 200 mg daily of oral micronized progesterone 1
- Administered for 12-14 days every 28 days (cyclical regimen) 1
- Can be given orally or vaginally at this dose 1
- Should be taken at bedtime to minimize drowsiness 2
Evidence Supporting 200 mg Dose
The 200 mg daily dose for 12-14 days per cycle has been validated for:
- Endometrial protection when combined with estrogen therapy for up to 5 years 3
- Adequate control of endometrial proliferation with minimal mitotic activity 4, 5
- High rates of amenorrhea (73-81% of cycles), which many patients prefer 5
Recent research specifically on adenomyosis demonstrates that intravaginal progesterone 200 mg/day for 10 days per cycle significantly improved all adenomyosis symptoms including dysmenorrhea, abnormal uterine bleeding, chronic pelvic pain, and dyspareunia 6.
Why Not 250 mg?
The 250 mg dose lacks supporting evidence:
- FDA-approved dosing for micronized progesterone ranges from 100-400 mg daily depending on indication 7
- For endometrial protection (the closest studied indication), doses are 200 mg for sequential regimens or 300 mg for withdrawal bleeding induction 7
- No studies have evaluated 250 mg specifically for adenomyosis or endometrial protection
Alternative Dosing Considerations
If 200 mg proves inadequate:
Higher dose option:
- 300 mg daily for 10 days per cycle can be used for inducing withdrawal bleeding 7
- This dose achieved 73.8% withdrawal bleeding rates in amenorrheic women 7
Continuous regimen:
- 100 mg daily for 25 days per month provides excellent endometrial control with high amenorrhea rates (73-81%) 4, 5
- This may be preferable for patients seeking to avoid monthly bleeding
Clinical Context for Adenomyosis
For adenomyosis specifically, progestin IUDs are clinically favored over oral progesterone due to:
- Local mechanism of action
- Lower systemic hormone levels
- Long duration after placement
- Superior improvement in pain and bleeding compared to combined oral contraceptives 8
However, if oral micronized progesterone is chosen, use 200 mg daily for 12-14 days per cycle, not 250 mg. The 200 mg dose provides adequate symptom control while maintaining the favorable safety profile of natural progesterone over synthetic progestins 1, 3, 2.
Important Caveats
- Progesterone resistance occurs in some adenomyosis patients, particularly those with advanced or extrinsic lesions 9
- Treatment response should be assessed after 1 month; lack of improvement suggests progesterone resistance 9
- Long-term progestin therapy may require switching between formulations due to side effects or reduced efficacy over time 10